ABSITE QUESTIONS WITH CORRECT
ANSWERS 2025
2NweeksNafterNaNwhippleNoperation,NyourNpatientNcontinuesNtoNhaveNearlyNsatietyNwithNoralNintake.NYouNd
ecideNtoNstartNmetoglopramideN(Reglan)NandNerythromycin.NWhatNreceptorNdoesNerythromycinNbindNtoNin
creaseNgastrointestinalNmotility?N-NcorrectNanswer-
MotilinN(foundNprimarilyNinNtheNstomach,Nduodenum,NandNcolon)
ProteinsNareNsynthesizedNfrom:
a.NmRNA
b.NtRNA
c.NdsDNA
d.NssDNAN-NcorrectNanswer-mRNA
1NweekNafterNanNAPR,NourNpatientNdevelopsNurosepsisNrequiringNvolumeNresuscitation,Nantibiotics,NandNm
oderateNamountsNofNlevophedNandNvasopressin.NE.NcoliNgrowsNoutNfromNtheNbloodNcultures.NWhatNportio
nNofNtheNlipopolysaccharideNcomplexNaccountsNforNitsNtoxicityN-NcorrectNanswer-
LipidNAN(withNgramNnegativeNsepsis;NstimulatorNofNTNFα)
SteroidNhormones:
a.NBindNaNreceptorNonNtheNplasmaNmembraneNandNactivateNaNplasmaNmembraneNenzyme
b.NBindNaNcytoplasmicNreceptor,NenterNtheNnucleus,NandNaffectNtranscriptionNofNproteins
c.NBindNaNreceptorNinNtheNnucleusNandNaffectNtranscriptionNofNproteins
d.NDoNnotNenterNtheNcellN-NcorrectNanswer-(b)
BindNaNreceptorNinNtheNcellNcytoplasm,NenterNtheNnucleusNasNaNsteroid-
receptorNcomplex,NandNaffectNtranscriptionNofNproteins
4NdaysNafterNanNIvor-LewisNesophagectomy,NyouNdecideNtoNstartNenteralNtubeNfeedingNthroughNaNJ-
tube.NTheNlongNchainNfattyNacidsNcontainedNinNtheNtubeNfeeds:
,a.NEnterNtheNcirculationNviaNtheNportalNsystem
b.NEnterNtheNcirculationNviaNlymphatics
c.NAreNonlyNsynthesizedNinNtheNbody
d.NAreNnotNfoundNinNchylomicronsN-NcorrectNanswer-(b)
Long-
chainNFAsNenterNtheNbodyNthroughNterminalNlactealsN(absorptionNthroughNtheNlymphaticNsystem)NeitherNa
sNfreeNLCFAsNorNasNchylomicrons
Medium-NandNshort-chainNFAsNalongNwithNproteins/CHONenterNthroughNtheNportalNcirculation
CellsNdivideNduringNwhatNphaseNofNtheNcellNcycle?
a.NG1
b.NS
c.NG2
d.NMN-NcorrectNanswer-(d)
CellsNdivideNduringNtheNMNphaseN(mostNradiosensitive)
CellNcycleNlengthNisNdeterminedNbyNwhatNphaseNofNtheNcellNcycle?
a.NG1
b.NS
c.NG2
d.NMN-NcorrectNanswer-(a)
G1N↔NG0NphaseNdeterminesNcellNcycleNlengthN(mostNvariableNcellNperiod)
,MostNRNA/proteinNsynthesis
OfNtheNfollowing,NwhichNisNtheNmostNcriticalNcomponentNinNtheNneovascularizationNofNtumorNmetastases?
a.NHERNreceptor
b.NVEGFNreceptor
c.NNeuNreceptor
d.NFGFNreceptorN-NcorrectNanswer-(d)
VascularNendothelialNgrowthNfactorN(VEGF)Nreceptor
ForNitsNanticoagulationNeffects,NheparinNbinds:
a.NProteinNC
b.NProteinNS
c.NAnti-thrombinNIII
d.NFactorNVIIN-NcorrectNanswer-(c)
ATIIIN(heparin-ATIIINcomplexNbindsNthrombin,NfactorNIX,NfactorNX,NandNfactorNXI)
7NdaysNafterNaNkidneyNtransplant,NyourNpatientNdevelopsNsevereNacuteNrejectionNwithNvasculitisNonNbiopsy.
NYouNdecideNtoNstartNtheNmonoclonalNantibodyNOKT3.NMonoclonalNantibodies:
a.NBindN1NepitopeNatNoneNsite
b.NBindN1NepitopeNatNmultipleNsites
c.NBindNmultipleNepitopesNonNaNsingleNantigen
d.NBindNmultipleNepitopesNonNmultipleNantigensN-NcorrectNanswer-(a)
, TheyNbindNoneNepitopeNatNtheNexactNsameNbindingNsite
YouNstartNcoumadinNonNaNpatientNwithNaNpulmonaryNembolus.NThreeNdaysNlater,NheNstartsNsloughingNoffNs
kinNacrossNhisNarmsNandNlegs.NAllNofNtheNfollowingNareNtrueNofNthisNpatientsNmostNlikelyNconditionNexcept:
a.NThisNlikelyNwouldNhaveNbeenNpreventedNbyNstartingNheparinNbeforeNcoumadin
b.NPatientsNwithNproteinNCNdeficiencyNareNmoreNsusceptibleNtoNthisNproblem
c.NTheNskinNsloughingNisNcausedNbyNskinNnecrosis
d.NThisNisNlikelyNdueNtoNhemophiliaNAN-NcorrectNanswer-(d)
Coumadin-
inducedNskinNnecrosisNoccursNinNpatientsNstartedNonNcoumadinNwithoutNbeingNgivenNheparinNfirst.NItNresul
tsNfromNaNrelativelyNhypercoagulableNstateNthatNcanNoccurNinNsomeNindividualsNbecauseNofNtheNshorterNha
lf-
lifeNofNproteinNCN&NSNcomparedNtoNfactorsNII,NVII,NIX,NandNX.NProteinNCN&NSN↓NafterNcoumadinNbeforeNtheN
otherNfactorsN↓,NresultingNinNaNrelativelyNhypercoagulableNstate.
WhileNperformingNaNLARNforNcolonNcancerNinNaNpatientNonNchronicNdialysis,NyouNnoticeNaNsignificantNamou
ntNofNbloodyNoozingNfromNyourNdissectionNplane.NAllNofNtheNfollowingNareNtrueNofNuremicNinducedNplatelet
NdysfunctionNexcept:
a.NDownNregulatesNGpIb
b.NDownNregulatesNGpIIb/IIIa
c.NStimulatesNvonNWillebrand'sNfactorNrelease
d.NTreatmentNofNchoiceNisNdialysisN-NcorrectNanswer-(c)
UremiaNdownregulatesNGpIb,NGpIIb/IIIa,NandNvWF
DialysisNisNtheNinitialNtreatmentNofNchoiceNforNuremicNcoagulopathy.NOtherNtherapeuticNoptionsNincludeND
DAVPNandNconjugatedNestrogensN(whichNstimulateNtheNreleaseNofNfactorNVIIINandNvWF).
TheNmostNcommonNbloodNtransfusionNreactionNis:
ANSWERS 2025
2NweeksNafterNaNwhippleNoperation,NyourNpatientNcontinuesNtoNhaveNearlyNsatietyNwithNoralNintake.NYouNd
ecideNtoNstartNmetoglopramideN(Reglan)NandNerythromycin.NWhatNreceptorNdoesNerythromycinNbindNtoNin
creaseNgastrointestinalNmotility?N-NcorrectNanswer-
MotilinN(foundNprimarilyNinNtheNstomach,Nduodenum,NandNcolon)
ProteinsNareNsynthesizedNfrom:
a.NmRNA
b.NtRNA
c.NdsDNA
d.NssDNAN-NcorrectNanswer-mRNA
1NweekNafterNanNAPR,NourNpatientNdevelopsNurosepsisNrequiringNvolumeNresuscitation,Nantibiotics,NandNm
oderateNamountsNofNlevophedNandNvasopressin.NE.NcoliNgrowsNoutNfromNtheNbloodNcultures.NWhatNportio
nNofNtheNlipopolysaccharideNcomplexNaccountsNforNitsNtoxicityN-NcorrectNanswer-
LipidNAN(withNgramNnegativeNsepsis;NstimulatorNofNTNFα)
SteroidNhormones:
a.NBindNaNreceptorNonNtheNplasmaNmembraneNandNactivateNaNplasmaNmembraneNenzyme
b.NBindNaNcytoplasmicNreceptor,NenterNtheNnucleus,NandNaffectNtranscriptionNofNproteins
c.NBindNaNreceptorNinNtheNnucleusNandNaffectNtranscriptionNofNproteins
d.NDoNnotNenterNtheNcellN-NcorrectNanswer-(b)
BindNaNreceptorNinNtheNcellNcytoplasm,NenterNtheNnucleusNasNaNsteroid-
receptorNcomplex,NandNaffectNtranscriptionNofNproteins
4NdaysNafterNanNIvor-LewisNesophagectomy,NyouNdecideNtoNstartNenteralNtubeNfeedingNthroughNaNJ-
tube.NTheNlongNchainNfattyNacidsNcontainedNinNtheNtubeNfeeds:
,a.NEnterNtheNcirculationNviaNtheNportalNsystem
b.NEnterNtheNcirculationNviaNlymphatics
c.NAreNonlyNsynthesizedNinNtheNbody
d.NAreNnotNfoundNinNchylomicronsN-NcorrectNanswer-(b)
Long-
chainNFAsNenterNtheNbodyNthroughNterminalNlactealsN(absorptionNthroughNtheNlymphaticNsystem)NeitherNa
sNfreeNLCFAsNorNasNchylomicrons
Medium-NandNshort-chainNFAsNalongNwithNproteins/CHONenterNthroughNtheNportalNcirculation
CellsNdivideNduringNwhatNphaseNofNtheNcellNcycle?
a.NG1
b.NS
c.NG2
d.NMN-NcorrectNanswer-(d)
CellsNdivideNduringNtheNMNphaseN(mostNradiosensitive)
CellNcycleNlengthNisNdeterminedNbyNwhatNphaseNofNtheNcellNcycle?
a.NG1
b.NS
c.NG2
d.NMN-NcorrectNanswer-(a)
G1N↔NG0NphaseNdeterminesNcellNcycleNlengthN(mostNvariableNcellNperiod)
,MostNRNA/proteinNsynthesis
OfNtheNfollowing,NwhichNisNtheNmostNcriticalNcomponentNinNtheNneovascularizationNofNtumorNmetastases?
a.NHERNreceptor
b.NVEGFNreceptor
c.NNeuNreceptor
d.NFGFNreceptorN-NcorrectNanswer-(d)
VascularNendothelialNgrowthNfactorN(VEGF)Nreceptor
ForNitsNanticoagulationNeffects,NheparinNbinds:
a.NProteinNC
b.NProteinNS
c.NAnti-thrombinNIII
d.NFactorNVIIN-NcorrectNanswer-(c)
ATIIIN(heparin-ATIIINcomplexNbindsNthrombin,NfactorNIX,NfactorNX,NandNfactorNXI)
7NdaysNafterNaNkidneyNtransplant,NyourNpatientNdevelopsNsevereNacuteNrejectionNwithNvasculitisNonNbiopsy.
NYouNdecideNtoNstartNtheNmonoclonalNantibodyNOKT3.NMonoclonalNantibodies:
a.NBindN1NepitopeNatNoneNsite
b.NBindN1NepitopeNatNmultipleNsites
c.NBindNmultipleNepitopesNonNaNsingleNantigen
d.NBindNmultipleNepitopesNonNmultipleNantigensN-NcorrectNanswer-(a)
, TheyNbindNoneNepitopeNatNtheNexactNsameNbindingNsite
YouNstartNcoumadinNonNaNpatientNwithNaNpulmonaryNembolus.NThreeNdaysNlater,NheNstartsNsloughingNoffNs
kinNacrossNhisNarmsNandNlegs.NAllNofNtheNfollowingNareNtrueNofNthisNpatientsNmostNlikelyNconditionNexcept:
a.NThisNlikelyNwouldNhaveNbeenNpreventedNbyNstartingNheparinNbeforeNcoumadin
b.NPatientsNwithNproteinNCNdeficiencyNareNmoreNsusceptibleNtoNthisNproblem
c.NTheNskinNsloughingNisNcausedNbyNskinNnecrosis
d.NThisNisNlikelyNdueNtoNhemophiliaNAN-NcorrectNanswer-(d)
Coumadin-
inducedNskinNnecrosisNoccursNinNpatientsNstartedNonNcoumadinNwithoutNbeingNgivenNheparinNfirst.NItNresul
tsNfromNaNrelativelyNhypercoagulableNstateNthatNcanNoccurNinNsomeNindividualsNbecauseNofNtheNshorterNha
lf-
lifeNofNproteinNCN&NSNcomparedNtoNfactorsNII,NVII,NIX,NandNX.NProteinNCN&NSN↓NafterNcoumadinNbeforeNtheN
otherNfactorsN↓,NresultingNinNaNrelativelyNhypercoagulableNstate.
WhileNperformingNaNLARNforNcolonNcancerNinNaNpatientNonNchronicNdialysis,NyouNnoticeNaNsignificantNamou
ntNofNbloodyNoozingNfromNyourNdissectionNplane.NAllNofNtheNfollowingNareNtrueNofNuremicNinducedNplatelet
NdysfunctionNexcept:
a.NDownNregulatesNGpIb
b.NDownNregulatesNGpIIb/IIIa
c.NStimulatesNvonNWillebrand'sNfactorNrelease
d.NTreatmentNofNchoiceNisNdialysisN-NcorrectNanswer-(c)
UremiaNdownregulatesNGpIb,NGpIIb/IIIa,NandNvWF
DialysisNisNtheNinitialNtreatmentNofNchoiceNforNuremicNcoagulopathy.NOtherNtherapeuticNoptionsNincludeND
DAVPNandNconjugatedNestrogensN(whichNstimulateNtheNreleaseNofNfactorNVIIINandNvWF).
TheNmostNcommonNbloodNtransfusionNreactionNis:
